Christian Antoni
About
In The Last Decade
Christian Antoni
47 papers receiving 8.9k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Rheumatology 5.7k
- Immunology 4.4k
- Hematology 2.9k
- Radiology, Nuclear Medicine and Imaging 830
- Molecular Biology 802
Countries citing papers authored by Christian Antoni
This map shows the geographic impact of Christian Antoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Antoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Antoni more than expected).
Fields of papers citing papers by Christian Antoni
This network shows the impact of papers produced by Christian Antoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Antoni. The network helps show where Christian Antoni may publish in the future.
Co-authorship network of co-authors of Christian Antoni
This figure shows the co-authorship network connecting the top 25 collaborators of Christian Antoni. A scholar is included among the top collaborators of Christian Antoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Antoni. Christian Antoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) | European Respiratory Journal | Ganesh Raghu, Luca Richeldi et al. | 70 |
| 2 | Effect of IL-17A blockade with secukinumab in autoimmune diseases | Annals of the Rheumatic Diseases | Dhavalkumar D. Patel, David M. Lee et al. | 248 |
| 3 | Standardization of Joint Examination Technique Leads to a Significant Decrease in Variability Among Different Examiners | The Journal of Rheumatology | Mathias Grünke, Christian Antoni et al. | 31 |
| 4 | An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status | Clinical Rheumatology | A. E. van der Bijl, Ferdinand C. Breedveld et al. | 69 |
| 5 | Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2 | Arthritis & Rheumatism | Désirée van der Heijde, Arthur Kavanaugh et al. | 140 |
| 6 | Leukocyte Infiltration and mRNA Expression of IL-20, IL-8 and TNF-R p60 in Psoriatic Skin is Driven by TNF-α | International Journal of Immunopathology and Pharmacology | Adaling Ogilvie, Matthias Lüftl et al. | 37 |
| 7 | Infliximab therapy improves health-related quality of life in patients with psoriatic arthritis | Journal of the American Academy of Dermatology | Dafna D. Gladman, Christian Antoni et al. | 2 |
| 8 | Infections in patients with rheumatoid arthritis treated with biologic agents breakdown → | Arthritis & Rheumatism | Joachim Listing, Anja Strangfeld et al. | 512 |
| 9 | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) breakdown → | Arthritis & Rheumatism | Christian Antoni, Arthur Kavanaugh et al. | 502 |
| 10 | Treatment continuation in patients receiving biological agents or conventional DMARD therapy | Annals of the Rheumatic Diseases | A. Zink, Joachim Listing et al. | 126 |
| 11 | Biotechnologische Medikamente bei entz�ndlichen Erkrankungen | Der Internist | Christian Antoni, Bernhard Manger | 0 |
| 12 | Langzeitergebnisse einer TNF-Blockade beim Morbus Still im Erwachsenenalter | DMW - Deutsche Medizinische Wochenschrift | Claudia Dechant, Christian Antoni et al. | 27 |
| 13 | Long‐term anti–tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion | Arthritis & Rheumatism | Rainer H. Straub, Georg Pongratz et al. | 45 |
| 14 | Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFα-antibody and methotrexate therapy | American Journal of Ophthalmology | Claus Cursiefen, Mathias Grünke et al. | 38 |
| 15 | Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences | Annals of the Rheumatic Diseases | Christian Antoni, J. R. Kalden et al. | 107 |
| 16 | Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. | PubMed | P. Charles, M. J. Elliott et al. | 440 |
| 17 | Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF-α Therapy in Rheumatoid Arthritis | The Journal of Immunology | P. Charles, Michael J. Elliott et al. | 376 |
| 18 | Graft-versus-Host-Like Mucocutaneous Eruptions with Serological Features of Paraneoplastic Pemphigus and Systemic Lupus erythematosus in a Patient with Non-Hodgkin’s Lymphoma | Dermatology | Vera Mahler, Christian Antoni et al. | 15 |
| 19 | In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects | The Journal of Immunology | Hanns‐Martin Lorenz, Christian Antoni et al. | 135 |
| 20 | Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis breakdown → | The Lancet | Michael J. Elliott, Ravinder N. Maini et al. | 1339 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.